ThomasJWalshMD
Infectious Disease • New York, NYAssistant Professor, Medicine, Weill Cornell Medical College
Are you Dr. Walsh?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1300 York Ave
A421
New York, NY 10065Phone+1 212-746-7736Fax+1 212-746-8852
Summary
- Dr. Thomas Walsh, MD is an infectious disease specialist in New York, New York. He is currently licensed to practice medicine in New York, Illinois, and Maryland. He is affiliated with New York-Presbyterian Hospital and is an Assistant Professor at Weill Cornell Medical College.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
University of MarylandFellowship, Hematology and Medical Oncology, 1985 - 1986- University of MarylandFellowship, Infectious Disease, 1984 - 1985
- University of MarylandFellowship, Infectious Disease, 1982 - 1983
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1980 - 1982- Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1978 - 1979
Johns Hopkins University School of MedicineClass of 1978
Certifications & Licensure
NY State Medical License 2010 - 2022
MD State Medical License 1979 - 2017
IL State Medical License 1980 - 1984
Clinical Trials
- Clinical Trials to Reduce the Risk of Antimicrobial Resistance Start of enrollment: 2010 Sep 01
- Doxycycline for COPD in HIV-Infected Patients Start of enrollment: 2014 Dec 08
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Start of enrollment: 2022 Jul 20
Publications & Presentations
PubMed
- 4 citationsFood and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.Caroline J Jjingo, Shukal Bala, Ursula Waack, Mark Needles, Timothy J Bensman
Clinical Infectious Diseases. 2024-06-14 - Development of rabbit models of ventilator-associated bacterial pneumonia produced by carbapenem-resistant.Vidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, Ethan Naing, Andrew Garcia
Antimicrobial Agents and Chemotherapy. 2024-06-05 - Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit.Rob Purdie, Lisa A Tushla, Jonathan Ferretti, Gonzalo Kiko Castro, Ricky Watson
Open Forum Infectious Diseases. 2024-06-01
Authored Content
- Isolated Cutaneous Mucormycosis in a Pediatric Renal Transplant RecipientMarch 2018
- Polymyxin B and Fosfomycin Thwart KPC-Producing Klebsiella Pneumoniae in the Hollow Fibre Infection ModelFebruary 2018
Press Mentions
Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal TherapyDecember 15th, 2022- Osteoarticular MycosesNovember 30th, 2022
- T2 Biosystems Announces Formation and Members of Scientific Advisory BoardApril 28th, 2022
- Join now to see all
